About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Role of AT1-receptor Blockers in Insulin-induced Vasodilation.

NCT00742066·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Maastricht University Medical Center

Age

18–60

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

hypertensive subjects:
1. 18-60 years
2. Caucasian
3. untreated hypertension \>140/90mmHg.
normotensive subjects:
1. 18-60 years
2. Caucasian
3. Blood pressure \<140/90 mmHg.

You may not be if

1. Obesity (BMI\>27kg/m2)
2. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
3. Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
4. Smoking
5. Alcohol use \>4U/day
6. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
7. Pregnancy
8. Wearing contact lenses

The record

StatusUnknown

PhaseNo phase

Taking part32

StartedMar 2008

UpdatedMar 17, 2011

Conditions

Hypertension Insulin Resistance Microcirculation

Where1

University Hospital Maastricht
Maastricht, P.O. Box 5800, Netherlands

Clareo Health | Role of AT1-receptor Blockers in Insulin-induced Vasodilation.